Effects of edaravone dexborneol on functional outcome and inflammatory response in patients with acute ischemic stroke

• Published in: BMC neurology 2024-06, Vol.24 (1), p.209-8, Article 209
• Main Authors: Chen, Wenxia, Zhang, Hanqing, Li, Zhenzhen, Deng, Qiwen, Wang, Meng, Chen, Yingbin, Zhang, Yuan
• Format: Article
• Language: English
• Subjects: Acute ischemic stroke; Aged; Analysis; Brain damage; Care and treatment; Clinical outcomes; Complications and side effects; Cytokines - metabolism; Edaravone - administration & dosage; Edaravone - pharmacology; Edaravone - therapeutic use; Edaravone dexborneol; Female; Functional outcome; Humans; Inflammation; Inflammation - drug therapy; Inflammatory response; Interleukin; Interleukin 10; Interleukin 12; Interleukin 17; Interleukin 2; Interleukin 4; Interleukin 5; Interleukin 6; Interleukin 8; Interleukins; Ischemia; Ischemic Stroke - drug therapy; Male; Middle Aged; Modified Rankin Scale; Mortality; Neuroprotection; Neuroprotective Agents - administration & dosage; Neuroprotective Agents - therapeutic use; Prevention; Risk factors; Stroke; Stroke (Disease); Treatment Outcome; Tumor necrosis factor-TNF; Tumor necrosis factor-α; α-Interferon; γ-Interferon
• ISSN: 1471-2377; 1471-2377
• DOI: 10.1186/s12883-024-03712-1

Edaravone dexborneol has been reported as an effective neuroprotective agent in the treatment of acute ischemic stroke (AIS). This study aimed at investigating the impact of edaravone dexborneol on functional outcomes and systematic inflammatory response in AIS patient. All participants were recruited from the AISRNA study (registered 21/11/2019, NCT04175691 [ClinicalTrials.gov]) between January 2022 and December 2022. The AIS patients were divided into two groups based on whether they received the treatment of edaravone dexborneol (37.5 mg/12 hours, IV) within 48 h after stroke onset. Inflammatory response was determined by detecting levels of cytokines (interleukin-2 [IL-2], IL-4, IL-5, IL-8, IL-6, IL-10, IL-12p70, IL-17, tumor necrosis factor-α [TNF-α], interferon-γ [IFN-γ], IFN-α, and IL-1β) within 14 days after stroke onset. Eighty-five AIS patients were included from the AISRNA study. Patients treated with edaravone dexborneol showed a significantly higher proportion of modified Rankin Scale score